Clinical observation of different doses of rituximab for the treatment of severe pemphigus: A single-center prospective cohort study

J Am Acad Dermatol. 2023 Feb;88(2):500-502. doi: 10.1016/j.jaad.2022.06.1187. Epub 2022 Jun 30.

Authors

Jiao Zhang¹, Xueyi Huang¹, Zeqiao Zhang¹, Peizhen Zhao¹, Wenjing Chen¹, Yunsheng Liang¹, Hongfang Liu¹, Zemin Zhong¹, Yongfeng Chen²

Affiliations

¹ Dermatology Hospital of Southern Medical University, Guangzhou, People's Republic of China.
² Dermatology Hospital of Southern Medical University, Guangzhou, People's Republic of China. Electronic address: gdcyf@163.com.

PMID: 35779637
DOI: 10.1016/j.jaad.2022.06.1187

No abstract available

Keywords: anti-CD20; autoimmune bullous disease; pemphigus; prospective cohort; rituximab; treatment.

MeSH terms

Antibodies, Monoclonal / therapeutic use
Humans
Immunologic Factors / therapeutic use
Pemphigus* / drug therapy
Prospective Studies
Rituximab / therapeutic use

Substances

Rituximab
Immunologic Factors
Antibodies, Monoclonal